Metastatic Urothelial cancer

Updated: July 13, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

erdafitinib

Initial:

oral

once a day

Dose Adjustments

After 14 to 21 days: 9 mg oral once a day (if serum phosphate < 5.5 mg/dl and no ocular disorder).

enfortumab vedotin

In combination with pembrolizumab
Indicated in patients with metastatic urothelial carcinoma, in patients who cannot take chemotherapy that contains cisplatin
1.25 mg/kg intravenously on the 1st and 8th day of a 28 days cycle
For more than 100 kg, do not exceed a dose of more than 125mg/dose
Administer half an hour before pembrolizumab if it is taken on the same day
As a single-agent therapy
Indicated in patients with metastatic urothelial carcinoma, in patients who cannot take chemotherapy that contains cisplatin
1.25 mg/kg intravenously on the 1st and 8th day of a 28 days cycle
For more than 100 kg, do not exceed a dose of more than 125mg/dose

Dose Modifications
1st dose reduction- 1mg/kg-100 mg
2nd dose reduction- 0.75mg/kg-75 mg
3rd dose reduction- 0.5mg/kg-50 mg